Cemiplimab Exhibits Long-Term Clinical Benefit in Advanced NSCLC Trial ByMiranda Gogishvili, MDApril 11th 2026Data from the EMPOWER-Lung 1 study reinforce the value of long-term immune checkpoint inhibition in PD-L1–high non–small cell lung cancer.